381 related articles for article (PubMed ID: 25625925)
1. Potential for immunotherapy in soft tissue sarcoma.
Tseng WW; Somaiah N; Engleman EG
Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Sarcoma: Future Horizons.
Burgess M; Gorantla V; Weiss K; Tawbi H
Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.
Yu Z; Ren P; Zhang X; Zhang T; Ma B
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1065-71. PubMed ID: 19671026
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away.
Lee A; Huang P; DeMatteo RP; Pollack SM
Am Soc Clin Oncol Educ Book; 2016; 35():281-90. PubMed ID: 27249707
[TBL] [Abstract][Full Text] [Related]
7. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
Maki RG
Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
9. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
Front Immunol; 2018; 9():1179. PubMed ID: 29896199
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunotherapy for soft tissue sarcomas.
Finkelstein SE; Fishman M; Conley AP; Gabrilovich D; Antonia S; Chiappori A
Immunotherapy; 2012 Mar; 4(3):283-90. PubMed ID: 22401634
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
12. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
13. A review of dendritic cell therapy for cancer: progress and challenges.
Mantia-Smaldone GM; Chu CS
BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
[TBL] [Abstract][Full Text] [Related]
14. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
15. DC therapy for prostate cancer.
Swindle PW; Tepes S; Clements J
Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
17. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell immunotherapy in soft tissue sarcoma.
Indelicato DJ; Finkelstein SE
Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy against sarcomas.
Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
